
Augurex Life Sciences Corp.
- Home
- Companies
- Augurex Life Sciences Corp.
- Products
- Augurex - Model 14-3-3 - Extracellular ...
Augurex - Model 14-3-3 - Extracellular Perpetuates Disease Protein - Rheumatoid Arthritis Blood Test
Extracellular 14-3-3η protein is a potent ligand and activator of intracellular signalling pathways that lead to the up-regulation of inflammation and joint damage factors involved in RA pathogenesis. The 14-3-3η blood test is clinically available as a diagnostic test whereby a positive result indicates a 5 to 50 times greater likelihood of having RA and informs joint damage prognosis and disease monitoring. 14-3-3η is used in combination with other serological tests and clinical assessment to support RA patient management.
Most popular related searches
rheumatoid arthritis
blood testing
blood test
arthritis rheumatoid
arthritis
clinical outcome
arthritis associated
lupus erythematosus
serological test
disease monitoring
Risk of RA
Diagnosis
- 14-3-3η is a Novel Mediator Associated with the Pathogenesis of Rheumatoid Arthritis and Joint Damage
- Review: 14-3-3η – a Novel Biomarker Platform for Rheumatoid Arthritis
- Serum 14-3-3η is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis
- 14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis
- The Diagnostic Value of 14-3-3η Protein Levels in Patients with Rheumatoid Arthritis
- Serum 14-3-3η Protein is Associated with Clinical and Serologic Features of Sjögren’s Syndrome in Patients with Systemic Lupus Erythematosus: A Cross-Sectional Analysis
Prognosis
- Serum Levels of 14-3-3η Protein Supplement C-reactive Protein and Rheumatoid Arthritis-Associated Antibodies to Predict Clinical and Radiographic Outcomes in a Prospective Cohort of Patients with Recent-Onset Inflammatory Polyarthritis
- Impending Radiographic Erosive Progression Over the Following Year in a Cohort of Consecutive Patients with Inflammatory Polyarthritis: Prediction by Serum Biomarkers
Monitoring
- Serum 14-3-3η Level is Associated with Severity and Clinical Outcomes of Rheumatoid Arthritis, and its Pretreatment Level is Predictive of DAS28 Remission with Tocilizumab
- Decrease in 14-3-3η Protein Levels is Correlated with Improvement in Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib
- Correlation of Plasma 14-3-3η Levels with Disease Activity Measures in Methotrexate-Naïve RA Patients Treated with Upadacitinib Monotherapy in the Select-Early Phase 3 Study